Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192808 | 1.00 | LMNA (0.61) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL5155050 | 0.98 | LMNA (0.65) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| Bromide SCHEMBL17105097 | 0.98 | LMNA (0.62) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| SCHEMBL5074160 | 0.90 | LMNA (0.55) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| SCHEMBL4404405 | 0.86 | LMNA (0.62) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| Trifluoromethanesulfonic Acid SCHEMBL5674252 | 0.84 | LMNA (0.53) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| SCHEMBL5293777 | 0.80 | LMNA (0.61) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| Bromide SCHEMBL11580547 | 0.79 | PABPC1 (0.51) | LMNAL3MBTL1ALDH1A1KDM4EPABPC1 | |
| SCHEMBL2737208 | 0.79 | LMNA (0.92) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A | |
| SCHEMBL1525672 | 0.79 | ALDH1A1 (0.52) | LMNAL3MBTL1ALDH1A1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61286377-A | — | — | None | — | — | JP | disclosed |
| CN-113604518-B | Method for degrading dibenzothiophene by artificial nicotinamide cofactor-mediated enzymatic method | 郑州大学 | 2023-05-09 | — | — | CN | disclosed |
| CN-113604518-A | Method for degrading dibenzothiophene through artificial nicotinamide cofactor mediated enzymatic method | 郑州大学 | 2021-11-05 | — | — | CN | disclosed |
| CN-108350325-B | Adhesive-attached resin film and optical laminate comprising same | 住友化学株式会社 | 2021-08-10 | — | — | CN | disclosed |
| US-9981969-B2 | Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160108048-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2007006418-A1 | IONIC-LIQUID-CONTAINING PRODUCTS FOR DYEING AND/OR BRIGHTENING KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006131234-A1 | COSMETIC COMPOSITIONS COMPRISING IONIC LIQUIDS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-12-14 | — | — | WO | disclosed |
| US-4906342-A | Plating bath for electrodeposition of aluminum and plating process making use of the bath | NISSHIN STEEL CO., LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
| EP-0339535-A1 | Plating bath for electrodeposition of aluminum and plating process making use of the bath | NISSHIN STEEL CO., LTD. (JP) | 1989-11-02 | — | — | EP | disclosed |
| JP-S61286377-A | PRODUCTION OF HEXAHYDRONICOTINE | JAPAN TOBACCO INC | 1986-12-16 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108048-A1 | IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | CYP3A43, CYP3A4, CYP3A7 | LMNA 4540/4885L3MBTL1 4538/4885ALDH1A1 105/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | LMNA 2699/4885L3MBTL1 3768/4885ALDH1A1 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.